Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Crossref DOI link: https://doi.org/10.1007/s12325-023-02606-x
Published Online: 2023-08-12
Published Print: 2023-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Liu, Geoffrey
Lam, Vincent K. http://orcid.org/0000-0002-1319-2588
Funding for this research was provided by:
Pfizer
Text and Data Mining valid from 2023-08-12
Version of Record valid from 2023-08-12
Article History
Received: 20 July 2022
Accepted: 3 July 2023
First Online: 12 August 2023